Literature DB >> 32378128

Drug repurposing in cardiology.

B O van Driel1, J van der Velden2.   

Abstract

Entities:  

Year:  2020        PMID： 32378128      PMCID： PMC7202678          DOI： 10.1007/s12471-020-01430-0

Source DB:  PubMed          Journal:  Neth Heart J        ISSN： 1568-5888            Impact factor:   2.380


× No keyword cloud information.
  6 in total

1.  Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Iacopo Olivotto; Paolo G Camici; Piera Angelica Merlini; Claudio Rapezzi; Monica Patten; Vicent Climent; Gianfranco Sinagra; Benedetta Tomberli; Francisco Marin; Philipp Ehlermann; Lars S Maier; Alessandra Fornaro; Claudius Jacobshagen; Antonello Ganau; Luciano Moretti; Antonio Hernandez Madrid; Raffaele Coppini; Giorgio Reggiardo; Corrado Poggesi; Francesco Fattirolli; Luiz Belardinelli; Gianfranco Gensini; Alessandro Mugelli
Journal:  Circ Heart Fail       Date:  2018-01       Impact factor: 8.790

2.  Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.

Authors:  Raffaele Coppini; Luca Mazzoni; Cecilia Ferrantini; Francesca Gentile; Josè Manuel Pioner; Annunziatina Laurino; Lorenzo Santini; Valentina Bargelli; Matteo Rotellini; Gianluca Bartolucci; Claudia Crocini; Leonardo Sacconi; Chiara Tesi; Luiz Belardinelli; Jil Tardiff; Alessandro Mugelli; Iacopo Olivotto; Elisabetta Cerbai; Corrado Poggesi
Journal:  Circ Heart Fail       Date:  2017-03       Impact factor: 8.790

3.  Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.

Authors:  Caroline J Coats; Menelaos Pavlou; Oliver T Watkinson; Alexandros Protonotarios; Linda Moss; Rebecca Hyland; Khadija Rantell; Antonis A Pantazis; Maite Tome; William J McKenna; Michael P Frenneaux; Rumana Omar; Perry M Elliott
Journal:  JAMA Cardiol       Date:  2019-03-01       Impact factor: 14.676

4.  TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study.

Authors:  A A van de Bovenkamp; A J Bakermans; C P Allaart; A J Nederveen; W E M Kok; A C van Rossum; M L Handoko
Journal:  Neth Heart J       Date:  2020-06       Impact factor: 2.380

5.  Extra energy for hearts with a genetic defect: ENERGY trial.

Authors:  B O van Driel; A C van Rossum; M Michels; R Huurman; J van der Velden
Journal:  Neth Heart J       Date:  2019-04       Impact factor: 2.380

6.  Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.

Authors:  Khalid Abozguia; Perry Elliott; William McKenna; Thanh Trung Phan; Ganesh Nallur-Shivu; Ibrar Ahmed; Abdul R Maher; Kulvinder Kaur; Jenny Taylor; Anke Henning; Houman Ashrafian; Hugh Watkins; Michael Frenneaux
Journal:  Circulation       Date:  2010-10-04       Impact factor: 29.690
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.